Alex Pearson

2.6k total citations · 1 hit paper
22 papers, 1.3k citations indexed

About

Alex Pearson is a scholar working on Molecular Biology, Genetics and Cancer Research. According to data from OpenAlex, Alex Pearson has authored 22 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Genetics and 7 papers in Cancer Research. Recurrent topics in Alex Pearson's work include Fibroblast Growth Factor Research (9 papers), Advanced Breast Cancer Therapies (3 papers) and Genomic variations and chromosomal abnormalities (3 papers). Alex Pearson is often cited by papers focused on Fibroblast Growth Factor Research (9 papers), Advanced Breast Cancer Therapies (3 papers) and Genomic variations and chromosomal abnormalities (3 papers). Alex Pearson collaborates with scholars based in United Kingdom, United States and Netherlands. Alex Pearson's co-authors include Nicholas C. Turner, Rachel Sharpe, Alan Ashworth, Rachael Natrajan, Alan Mackay, Jorge S. Reis‐Filho, Felipe C. Geyer, Elizabeth Iorns, Maryou Lambros and Andrew Tutt and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Alex Pearson

22 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

2010 544 citations Nicholas C. Turner, Alex Pearson et al. Cancer Research profile →

Peers

Countries citing papers authored by Alex Pearson

Since Specialization

Citations

This map shows the geographic impact of Alex Pearson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Pearson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Pearson more than expected).

Fields of papers citing papers by Alex Pearson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Pearson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Pearson. The network helps show where Alex Pearson may publish in the future.

Co-authorship network of co-authors of Alex Pearson

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Pearson. A scholar is included among the top collaborators of Alex Pearson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Pearson. Alex Pearson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1 -Mutant Breast Cancer 2023 ·Cancer Discovery ·Belinda Kingston, Alex Pearson, María Teresa Herrera-Abreu, (unknown), Rosalind Cutts, (unknown), Laura Moretti, Lucy Kilburn, (unknown), Iain R. Macpherson, Alistair Ring, Judith M. Bliss, (unknown), Weiyi Toy, John A. Katzenellenbogen, Sarat Chandarlapaty, Nicholas C. Turner	21
2	ESR1 F404 mutations and acquired resistance to fulvestrant in the plasmaMATCH study. 2022 ·Journal of Clinical Oncology ·Belinda Kingston, Alex Pearson, María Teresa Herrera-Abreu, Ros Cutts, Laura Moretti, Lucy Kilburn, Hannah Johnson, Iain R. Macpherson, Alistair Ring, Judith M. Bliss, John A. Katzenellenbogen, Nicholas C. Turner	5
3	1O Detection of homologous recombination repair deficiency (HRD) in treatment-naive early triple-negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests 2021 ·Annals of Oncology ·(unknown), Alba Llop‐Guevara, Alex Pearson, Cristina Cruz, Marta Castroviejo‐Bermejo, Neha Chopra, Holly Tovey, Christy Toms, Divya Kriplani, Heidrun Gevensleben, Rebecca Roylance, Stephen Chan, Andrew Tutt, A. Skene, Abigail Evans, Helen Davies, Judith M. Bliss, Serena Nik‐Zainal, Judith Balmañà, Nicholas C. Turner	4
4	Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations 2018 ·British Journal of Cancer ·Elena López‐Knowles, Alex Pearson, Eugene F. Schuster, Pascal Gellert, Ricardo Ribas, Belinda Yeo, Ros Cutts, Richard Buus, Isaac García-Murillas, Ben P. Haynes, Lesley‐Ann Martin, Ian Smith, Nicholas C. Turner, Mitch Dowsett	12
5	FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment 2018 ·Breast Cancer Research and Treatment ·Anna Wilkins, Ritika Chauhan, Alistair G. Rust, Alex Pearson, Frances Daley, (unknown), Kerry Fenwick, Judith M. Bliss, John Yarnold, Navita Somaiah	4
6	Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results. 2016 ·Journal of Clinical Oncology ·Elizabeth Smyth, Nicholas C. Turner, Alex Pearson, Clare Peckitt, Ian Chau, David Watkins, Naureen Starling, (unknown), Angela Gillbanks, Elaine Kilgour, (unknown), Neil R. Smith, Ros Cutts, Claire Rooney, Anne Thomas, Mazhar Ajaz, Sue Chua, Gina Brown, Sanjay Popat, David Cunningham	15
7	145O Phase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results 2015 ·Annals of Oncology ·Elizabeth Smyth, Nicholas C. Turner, Alex Pearson, Clare Peckitt, Ian Chau, David Watkins, Elaine Kilgour, Neil R. Smith, Angela Gillbanks, Sue Chua, Gina Brown, Rosalind Cutts, Claire Rooney, (unknown), Anne Thomas, Sanjay Popat, David Cunningham	2
8	PI3 kinase/mTOR inhibition increases sensitivity of ER positive breast cancers to CDK4/6 inhibition by blocking cell cycle re-entry driven by cyclinD1 and inducing apoptosis 2015 ·Annals of Oncology ·María Teresa Herrera-Abreu, Uzma Asghar, (unknown), Alex Pearson, Michelle Nannini, (unknown), (unknown), Mitch Dowsett, Lesley‐Ann Martin, Nicholas C. Turner	6
9	Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition. 2015 ·Journal of Clinical Oncology ·Uzma Asghar, María Teresa Herrera-Abreu, Ros Cutts, Irina S. Babina, Alex Pearson, Nicholas C. Turner	18
10	Abstract C37: Molecular determinants of sensitivity and resistance to FGFR inhibition in FGFR2-amplified gastric cancer 2015 ·Molecular Cancer Therapeutics ·Irina S. Babina, Alex Pearson, Ros Cutts, Elizabeth Smyth, Jian Ning, Amanda Swain, David Cunningham, Nicholas C. Turner	1
11	Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3 -Mutant Cancer 2013 ·Cancer Discovery ·María Teresa Herrera-Abreu, Alex Pearson, James Campbell, Steven D. Shnyder, Margaret A. Knowles, Alan Ashworth, Nicholas C. Turner	98
12	An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer 2013 ·Oncogene ·Isaac García-Murillas, Rachel Sharpe, Alex Pearson, James Campbell, Rachael Natrajan, Alan Ashworth, Nicholas C. Turner	28
13	FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo 2011 ·Clinical Cancer Research ·Rachel Sharpe, Alex Pearson, María Teresa Herrera-Abreu, (unknown), Alan Mackay, Jonathan Welti, Rachael Natrajan, Andrew R. Reynolds, Jorge S. Reis‐Filho, Alan Ashworth, Nicholas C. Turner	144
14	FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer breakdown → 2010 ·Cancer Research ·Nicholas C. Turner, Alex Pearson, Rachel Sharpe, Maryou Lambros, Felipe C. Geyer, María Ángeles López‐García, Rachael Natrajan, Caterina Marchiò, Elizabeth Iorns, Alan Mackay, Cheryl Gillett, Anita Grigoriadis, Andrew Tutt, Jorge S. Reis‐Filho, Alan Ashworth	544
15	Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets 2010 ·Oncogene ·Nicholas C. Turner, Maryou B. Lambros, Hugo M. Horlings, Alex Pearson, Rachel Sharpe, Rachael Natrajan, Felipe C. Geyer, Marieke van Kouwenhove, Bas Kreike, Alan Mackay, Alan Ashworth, Marc J. van de Vijver, Jorge S. Reis‐Filho	322
16	Abstract P5-02-01: FGFR Signalling Drives the Growth of Triple Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo 2010 ·Cancer Research ·Nicholas C. Turner, Rachel Sharpe, David C. Johnson, Alex Pearson, Alan Ashworth	1
17	Integrative Molecular Profiling of Triple Negative Breast Cancers Identifies Potential Therapeutic Targets Including Amplifications of FGFR2. 2009 ·Cancer Research ·Nicholas C. Turner, Maryou Lambros, Hugo M. Horlings, Alex Pearson, Rachel Sharpe, Alan Mackay, (unknown), Felipe C. Geyer, Marieke van Kouwenhove, Bas Kreike, A. Ashworth, Marc J. van de Vijver, Jorge S. Reis‐Filho	1
18	MANAGEMENT OF SKIN TRAUMA 2000 ·Primary Care Clinics in Office Practice ·Alex Pearson, (unknown)	13
19	Chemotherapy in combination with pelvic irradiation: A time-dependence study in mice 1984 ·Radiotherapy and Oncology ·Alex Pearson, G. Gordon Steel	16
20	The Relationship between ‘Early’ and ‘Late’ Radiation-induced Skin Reactions as Seen in Two Strains of Mice That Differ in Radiosensitivity 1983 ·International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine ·Alex Pearson, G. Gordon Steel	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact